Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cetrorelix Pamoate · 1 trial · 1 indication
International Prostate Symptom Score (IPSS) Patient Questionnaire assessing 7 items (incomplete voiding, frequency, intermittency, urgency, weak stream, hesitancy, nocturia) on a scale from 0 (best) to 5 (worst); total range: 0 - 35 points; absolute change from baseline to Week 26
| Arm | Type | Description |
|---|---|---|
| Cetrorelix 78 mg | EXPERIMENTAL | Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26. |
| Name | Type | Description |
|---|---|---|
| Cetrorelix Pamoate | DRUG | Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2, |
Inclusion Criteria: * Benign Prostatic Hyperplasia, based on medical history * Voiding symptoms * Uroflow (max) 5-15mL/sec Exclusion Criteria: * Urgent need for prostate surgery * History of allergic reaction to peptide * Major organ dysfunction * Prior surgical treatment of the prostate or bladd...
Cetrorelix Pamoate is an investigational small molecule being studied for the treatment of symptomatic Benign Prostatic Hypertrophy (BPH), also known as benign prostatic hyperplasia. It is administered via intramuscular injection and is intended to address symptoms associated with an enlarged prostate.
Cetrorelix Pamoate is a gonadotropin-releasing hormone (GnRH) antagonist. It works by blocking GnRH receptors, which reduces the production of sex hormones like testosterone. This hormonal suppression is thought to help reduce prostate size and alleviate symptoms of Benign Prostatic Hypertrophy.
Cetrorelix Pamoate is being developed by COSCIENS Biopharma Inc., a biopharmaceutical company traded under the ticker symbol CSCI. The company is conducting clinical research to evaluate the drug's safety and efficacy for treating Benign Prostatic Hypertrophy.
Cetrorelix Pamoate is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the results will inform potential regulatory submissions for the treatment of Benign Prostatic Hypertrophy.
Cetrorelix Pamoate has been studied in one completed Phase 3 clinical trial with the identifier NCT00670306. This trial, titled 'Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH),' enrolled 528 male participants aged 50 years and older in the United States and Canada.